Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...

TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...

(Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare ...

Please provide your email address to receive an email when new articles are posted on . Transplant advocates said a language change in Medicare payment policy would limit availability of a test used ...

WASHINGTON -- Heart transplant patient Eddie Garcia was "feeling like a million bucks" one day in the summer of 2021. He had just gotten back from a 3-mile walk, something he couldn't do prior to his ...